Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Yang,Sun

第一单位： Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, California.

作者： Yang,Sun ^[1] ; David,Wirta ^[2] ; Wendy,Murahashi ^[3] ; Vidhu,Mathur ^[3] ; Sethu,Sankaranarayanan ^[3] ; Lori K,Taylor ^[3] ; Ted,Yednock ^[3] ; Donald S,Fong ^[3] ; Jeffrey L,Goldberg ^[1]

作者单位： Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, California. ^[1] Eye Research Foundation, Newport Beach, California. ^[2] Annexon Biosciences, Brisbane, California. ^[3]

关键词 ANX007 C1q Classical complement pathway Glaucoma Intravitreal injection

DOI 10.1016/j.xops.2023.100290

PMID 37124168

发布时间 2023-05-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Ophthalmology science

2023年3卷2期

100290页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma.

Ophthalmology science

相似文献

Ophthalmology science

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma.

Ophthalmology science

相似文献

Ophthalmology science

相关期刊

检索历史清除